Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

An immune proteomic atlas of 300 million bone marrow cells reveals prognostic cell states in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

WPWilliam PilcherEGEdgar Gonzalez‐KozlovaTKTaxiarchis Kourelis

Discussion

Loading...

Member takes

Overview

Analysis uncovers prognostic biomarkers linked to clinical outcomes in multiple myeloma, suggesting new therapeutic targets.

Key Points

  • Overall survival improved with higher naïve B cells and pDCs, while neutrophils correlated with worse outcomes.
  • Identified major immune populations in bone marrow including neutrophils, CD4 T cells, and B cells alongside important clinical factors.
  • Utilized CyTOF for comprehensive immune profiling in over 1,000 MM patients from a large-scale cohort.
  • Findings support targeting immune composition in treatment strategies for enhancing survival in multiple myeloma.

Cite This Study

Pilcher et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e42chttps://doi.org/10.1182/blood-2025-5801
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CyTOF profiling of bone marrow immune dynamics across myeloma stages2025 · 3 citations
  2. 2Multi-omics reveals immune features in immune and non-immune cells, an IFN-γ/IFN-α-B2M positive feedback loop, and targeted metabolic therapy in multiple myeloma2025
  3. 3Mapping the cytotoxic landscape: an integrated analysis of T cell heterogeneity in the bone marrow microenvironment of multiple myeloma 28102025
  4. 4Immune biomarkers of increased risk of infection in multiple myeloma (MM)2025
  5. 5Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy2025